141 related articles for article (PubMed ID: 20510315)
21. Human immunodeficiency virus type 1 replication and regulation of APOBEC3G by peptidyl prolyl isomerase Pin1.
Watashi K; Khan M; Yedavalli VR; Yeung ML; Strebel K; Jeang KT
J Virol; 2008 Oct; 82(20):9928-36. PubMed ID: 18684817
[TBL] [Abstract][Full Text] [Related]
22. Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.
Pery E; Sheehy A; Miranda Nebane N; Misra V; Mankowski MK; Rasmussen L; Lucile White E; Ptak RG; Gabuzda D
Virology; 2015 Oct; 484():276-287. PubMed ID: 26141568
[TBL] [Abstract][Full Text] [Related]
23. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
[TBL] [Abstract][Full Text] [Related]
24. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
Han Y; Wang X; Dang Y; Zheng YH
PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
[TBL] [Abstract][Full Text] [Related]
25. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.
Bonvin M; Achermann F; Greeve I; Stroka D; Keogh A; Inderbitzin D; Candinas D; Sommer P; Wain-Hobson S; Vartanian JP; Greeve J
Hepatology; 2006 Jun; 43(6):1364-74. PubMed ID: 16729314
[TBL] [Abstract][Full Text] [Related]
26. APOBEC-mediated interference with hepadnavirus production.
Rösler C; Köck J; Kann M; Malim MH; Blum HE; Baumert TF; von Weizsäcker F
Hepatology; 2005 Aug; 42(2):301-9. PubMed ID: 16025511
[TBL] [Abstract][Full Text] [Related]
27. The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.
Valera MS; de Armas-Rillo L; Barroso-González J; Ziglio S; Batisse J; Dubois N; Marrero-Hernández S; Borel S; García-Expósito L; Biard-Piechaczyk M; Paillart JC; Valenzuela-Fernández A
Retrovirology; 2015 Jun; 12():53. PubMed ID: 26105074
[TBL] [Abstract][Full Text] [Related]
28. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
[TBL] [Abstract][Full Text] [Related]
29. Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activity.
McDougall WM; Smith HC
Biochem Biophys Res Commun; 2011 Sep; 412(4):612-7. PubMed ID: 21856286
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif.
Shirakawa K; Takaori-Kondo A; Yokoyama M; Izumi T; Matsui M; Io K; Sato T; Sato H; Uchiyama T
Nat Struct Mol Biol; 2008 Nov; 15(11):1184-91. PubMed ID: 18836454
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms and Effects on HBV Replication of the Interaction between HBV Core Protein and Cellular Filamin B.
Li Y; Sun Y; Sun F; Hua R; Li C; Chen L; Guo D; Mu J
Virol Sin; 2018 Apr; 33(2):162-172. PubMed ID: 29594956
[TBL] [Abstract][Full Text] [Related]
32. Cell-Free Hepatitis B Virus Capsid Assembly Dependent on the Core Protein C-Terminal Domain and Regulated by Phosphorylation.
Ludgate L; Liu K; Luckenbaugh L; Streck N; Eng S; Voitenleitner C; Delaney WE; Hu J
J Virol; 2016 Jun; 90(12):5830-5844. PubMed ID: 27076641
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3G exerts tumor suppressive effects in human hepatocellular carcinoma.
Chang LC; Kuo TY; Liu CW; Chen YS; Lin HH; Wu PF
Anticancer Drugs; 2014 Apr; 25(4):456-61. PubMed ID: 24500029
[TBL] [Abstract][Full Text] [Related]
34. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
Ao Z; Yu Z; Wang L; Zheng Y; Yao X
PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671
[TBL] [Abstract][Full Text] [Related]
35. APOBEC3G is a restriction factor of EV71 and mediator of IMB-Z antiviral activity.
Wang H; Zhong M; Li Y; Li K; Wu S; Guo T; Cen S; Jiang J; Li Z; Li Y
Antiviral Res; 2019 May; 165():23-33. PubMed ID: 30862444
[TBL] [Abstract][Full Text] [Related]
36. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.
Wang T; Zhang W; Tian C; Liu B; Yu Y; Ding L; Spearman P; Yu XF
Virology; 2008 Jul; 377(1):71-9. PubMed ID: 18495196
[TBL] [Abstract][Full Text] [Related]
37. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
38. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G.
Henry M; Guétard D; Suspène R; Rusniok C; Wain-Hobson S; Vartanian JP
PLoS One; 2009; 4(1):e4277. PubMed ID: 19169351
[TBL] [Abstract][Full Text] [Related]
39. APOBEC3G-Regulated Host Factors Interfere with Measles Virus Replication: Role of REDD1 and Mammalian TORC1 Inhibition.
Tiwarekar V; Wohlfahrt J; Fehrholz M; Scholz CJ; Kneitz S; Schneider-Schaulies J
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925665
[TBL] [Abstract][Full Text] [Related]
40. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
